Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML von Dey, Aonkon, Narayan, Rupa, Smith, Neal, Tirard, Alice, Arnold, Benjamin, McGuire, John, Chan, Thomas, Lombardi Story, Jennifer, Casson, Timothy, Behnan, Tanya Toni, Fathi, Amir T., Hobbs, Gabriela S., Hock, Hanno, Amrein, Philip C., Reeves, Patrick, Graubert, Timothy Aaron, Brunner, Andrew M., Villani, Alexandra-Chloé

Volltext

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults von Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey G, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven, Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

Volltext

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults von Amrein, Philip C., Ballen, Karen K., Stevenson, Kristen E., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Graubert, Timothy A., Neuberg, Donna S., Fathi, Amir T.

Volltext

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults von Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

Volltext

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation von Fathi, Amir T., Blonquist, Traci M., Hernandez, Daniela, Amrein, Philip C., Ballen, Karen K., McMasters, Malgorzata, Avigan, David E., Joyce, Robin, Logan, Emma K., Hobbs, Gabriela, Brunner, Andrew M., Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Behnan, Tanya, Foster, Julia, Bergeron, Meghan K., Moran, Jenna A., Ramos, Aura Y., Som, Tina T., Rae, Jessica, Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Levis, Mark J.

Volltext

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia von Narayan, Rupa, Blonquist, Traci M., Emadi, Ashkan, Hasserjian, Robert P., Burke, Meghan, Lescinskas, Christopher, Neuberg, Donna S., Brunner, Andrew M., Hobbs, Gabriela, Hock, Hanno, McAfee, Steven L., Chen, Yi‐Bin, Attar, Eyal, Graubert, Timothy A., Bertoli, Christina, Moran, Jenna A., Bergeron, Meghan K., Foster, Julia E., Ramos, Aura Y., Som, Tina T., Vartanian, Megan K., Story, Jennifer L., McGregor, Kristin, Macrae, Molly, Behnan, Tanya, Wey, Margaret C., Rae, Jessica, Preffer, Frederic I., Lesho, Patricia, Duong, Vu H., Mann, Mason L., Ballen, Karen K., Connolly, Christine, Amrein, Philip C., Fathi, Amir T.

Volltext

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults von Amrein, Philip C., Ballen, Karen K., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Fathi, Amir T.

Volltext

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults von Amrein, Philip C., Attar, Eyal C., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S, Fathi, Amir T.

Volltext

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia von Fathi, Amir T., Blonquist, Traci M., Emadi, Ashkan, Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Hasserjian, Robert P., Preffer, Frederic I., Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Lesho, Patricia, Duong, Vu H., Mann, Mason, Lescinskas, Christopher, Connolly, Christine, Neuberg, Donna S, Ballen, Karen K., Amrein, Philip C.

Volltext

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia von Brunner, Andrew M., Blonquist, Traci M., DeAngelo, Daniel J., McMasters, Malgorzata, Winer, Eric S., Hobbs, Gabriela S., Amrein, Philip C., Hock, Hanno, Steensma, David P., Garcia, Jacqueline S., Luskin, Marlise R., Stone, Richard M., Ballen, Karen K., Rosenblatt, Jacalyn, Avigan, David E., McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Nelson, Nicole, Logan, Emma, Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin, Graubert, Timothy A., Fathi, Amir T.

Volltext

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial von Brunner, Andrew M, Blonquist, Traci M, DeAngelo, Daniel J, McMasters, Malgorzata, Fell, Geoffrey, Hermance, Nicole M, Winer, Eric S, Lindsley, R Coleman, Hobbs, Gabriela S, Amrein, Philip C, Hock, Hanno R, Steensma, David P, Garcia, Jacqueline S, Luskin, Marlise R, Stone, Richard M, Ballen, Karen K, Rosenblatt, Jacalyn, Avigan, David, Nahas, Myrna R, Mendez, Lourdes M, McAfee, Steven L, Moran, Jenna A, Bergeron, Meghan, Foster, Julia, Bertoli, Christina, Manning, Amity L, McGregor, Kristin L, Fishman, Kaitlyn M, Kuo, Frank C, Baltay, Michele T, Macrae, Molly, Burke, Meghan, Behnan, Tanya, Wey, Margaret C, Som, Tina T, Ramos, Aura Y, Rae, Jessica, Lombardi Story, Jennifer, Nelson, Nicole, Logan, Emma, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin, Graubert, Timothy A, Fathi, Amir T

Volltext